Skip to main content

Talvey News

FDA Provides Accelerated Approval of Talvey for Multiple Myeloma

TUESDAY, Aug. 15, 2023 – The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma. The accelerated approval is for...

FDA Approves Talvey (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

HORSHAM, Pa., Aug. 10, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Talvey™ (ta...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Multiple Myeloma

Talvey patient information at Drugs.com